Bong-Woo Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bong-Woo Park has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Hun-Jun Park
Department of biomedicine and health sciences, The Catholic University of Korea, Seoul 06591, Republic of Korea
15 shared publications - Kiwon Ban
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China
11 shared publications - Hyeok Kim
Center for Biomaterials, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea
7 shared publications - Woo-Sup Sim
Department of biomedicine and health sciences, The Catholic University of Korea, Seoul 06591, Republic of Korea
5 shared publications Jae-Hyun Park
Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
4 shared publications- Jae-Hyun Park
Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Host-compatible cardiac fibroblast-derived ECM patches promote myocardial repair after infarction
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHost-compatible cardiac fibroblast-derived ECM patches promote myocardial repair after infarction
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
- Open Access
- 2 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eady9664
Conserved stromal EMT program controls regenerative capacity of mesenchymal stromal cells across multiple tissues
The regenerative function of stem cells is orchestrated by specialized niches, yet the mechanisms underlying mesenchymal stromal cell (MSC)–mediated support remain unclear. Here, we demonstrate that the epithelial-to-mesenchymal transition (EMT) gradient, together with stemness and pericyte-like properties, is a critical regulator of MSC niche function. High EMT gradients characterize functional MSC subsets that functions as niche supporting hematopoietic stem cells (HSCs), while attenuation of the EMT program impairs HSC support and reproduced in degenerative hematological disorders. Notably, enhancing the EMT program in MSCs (aEMT-MSCs) markedly augments their capacity to promote HSC regeneration and restores defective niches in patients with aplastic anemia. Furthermore, the regenerative effects of aEMT-MSCs extend beyond hematopoiesis to neuronal and cardiovascular tissues, suggesting a conserved niche-supporting program across multiple tissue systems. These findings establish the EMT program as a central regulator of the mesenchymal niche and propose a strategy to address unmet needs in regenerative medicine.
- 2 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eady9664
Open AccessConserved stromal EMT program controls regenerative capacity of mesenchymal stromal cells across multiple tissues
The regenerative function of stem cells is orchestrated by specialized niches, yet the mechanisms underlying mesenchymal stromal cell (MSC)–mediated support remain unclear. Here, we demonstrate that the epithelial-to-mesenchymal transition (EMT) gradient, together with stemness and pericyte-like properties, is a critical regulator of MSC niche function. High EMT gradients characterize functional MSC subsets that functions as niche supporting hematopoietic stem cells (HSCs), while attenuation of the EMT program impairs HSC support and reproduced in degenerative hematological disorders. Notably, enhancing the EMT program in MSCs (aEMT-MSCs) markedly augments their capacity to promote HSC regeneration and restores defective niches in patients with aplastic anemia. Furthermore, the regenerative effects of aEMT-MSCs extend beyond hematopoiesis to neuronal and cardiovascular tissues, suggesting a conserved niche-supporting program across multiple tissue systems. These findings establish the EMT program as a central regulator of the mesenchymal niche and propose a strategy to address unmet needs in regenerative medicine.
- Open Access
- 31 May 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 671
Ultrafast ROS Scavenging Activity of Amur Maple Tree Extracts Confers Robust Cardioprotection for Myocardial Ischemia/Reperfusion Injury
Ginnalin A (GA), a polyphenolic compound derived from amur maple trees, has been identified as a powerful scavenger of reactive oxygen species (ROS). Recognizing the pivotal role of ROS in exacerbating secondary damage during myocardial ischemia-reperfusion injury (MIRI), we fractionated GA-enriched extracts from the leaves of the amur maple tree, Acer tataricum L. subsp. ginnala (Maxim.) Wesm., using common solvents of dichloromethane (DCM) and ethyl acetate (EA). When co-administered for 30 min, the DCM- and EA-fractioned extracts effectively protected cardiomyocytes from H2O2-induced damage. ROS-sensitive probes indicated that treatment with ginnala extracts significantly reduced both intracellular and mitochondrial ROS levels. Instead of enhancing the activity of antioxidative enzymes, the ginnala extracts acted as natural antioxidases, directly scavenging various ROS such as superoxide, H2O2, hydroxyl radical, and Fe2+ within just 20 min. In a MIRI rat model, the in vivo administration of ginnala extracts provided significant cardioprotection by preserving viable myocardia and enhancing cardiac functions. Additionally, treatment with ginnala extracts significantly reduced cardiac fibrosis and denatured collagen. Our study suggests that the ultrafast ROS scavenging capability of ginnala extracts offers substantial heart protection during MIRI. Incorporating ginnala extracts as a pharmacological intervention during reperfusion could effectively mitigate ROS-induced cardiac injury.
- 31 May 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 671
Open AccessUltrafast ROS Scavenging Activity of Amur Maple Tree Extracts Confers Robust Cardioprotection for Myocardial Ischemia/Reperfusion Injury
Ginnalin A (GA), a polyphenolic compound derived from amur maple trees, has been identified as a powerful scavenger of reactive oxygen species (ROS). Recognizing the pivotal role of ROS in exacerbating secondary damage during myocardial ischemia-reperfusion injury (MIRI), we fractionated GA-enriched extracts from the leaves of the amur maple tree, Acer tataricum L. subsp. ginnala (Maxim.) Wesm., using common solvents of dichloromethane (DCM) and ethyl acetate (EA). When co-administered for 30 min, the DCM- and EA-fractioned extracts effectively protected cardiomyocytes from H2O2-induced damage. ROS-sensitive probes indicated that treatment with ginnala extracts significantly reduced both intracellular and mitochondrial ROS levels. Instead of enhancing the activity of antioxidative enzymes, the ginnala extracts acted as natural antioxidases, directly scavenging various ROS such as superoxide, H2O2, hydroxyl radical, and Fe2+ within just 20 min. In a MIRI rat model, the in vivo administration of ginnala extracts provided significant cardioprotection by preserving viable myocardia and enhancing cardiac functions. Additionally, treatment with ginnala extracts significantly reduced cardiac fibrosis and denatured collagen. Our study suggests that the ultrafast ROS scavenging capability of ginnala extracts offers substantial heart protection during MIRI. Incorporating ginnala extracts as a pharmacological intervention during reperfusion could effectively mitigate ROS-induced cardiac injury.
- Open Access
- 27 January 2023
- Published by Wiley in Advanced Functional Materials
- Vol. 33 (23)
Targeted Delivery of Apoptotic Cell‐Derived Nanovesicles prevents Cardiac Remodeling and Attenuates Cardiac Function Exacerbation
The modulation of inflammatory responses plays an important role in the pathobiology of cardiac failure. In a natural healing process, the ingestion of apoptotic cells and their apoptotic bodies by macrophages in a focal lesion result in resolution of inflammation and regeneration. However, therapeutic strategies to enhance this natural healing process using apoptotic cell‐derived biomaterials have not yet been established. In this study, apoptotic bodies‐mimetic nanovesicles derived from apoptotic fibroblasts (ApoNVs) conjugated with dextran and ischemic cardiac homing peptide (CHP) (ApoNV‐DCs) for ischemia‐reperfusion (IR)‐injured heart treatment are developed. Intravenously injected ApoNV‐DCs actively targeted the ischemic myocardium via conjugation with CHP, and are selectively phagocytosed by macrophages in an infarcted myocardium via conjugation with dextran. ApoNV‐DCs polarized macrophages from the M1 to M2 phenotype, resulting in the attenuation of inflammation. Four weeks after injection, ApoNV‐DCs attenuated cardiac remodeling, preserved blood vessels, and prevented cardiac function exacerbation in IR‐injured hearts. Taken together, the findings may open a new avenue for immunomodulation using targeted delivery of anti‐inflammatory nanovesicles that can be universally applied for various inflammatory diseases.
- 27 January 2023
- Published by Wiley in Advanced Functional Materials
- Vol. 33 (23)
Open AccessTargeted Delivery of Apoptotic Cell‐Derived Nanovesicles prevents Cardiac Remodeling and Attenuates Cardiac Function Exacerbation
The modulation of inflammatory responses plays an important role in the pathobiology of cardiac failure. In a natural healing process, the ingestion of apoptotic cells and their apoptotic bodies by macrophages in a focal lesion result in resolution of inflammation and regeneration. However, therapeutic strategies to enhance this natural healing process using apoptotic cell‐derived biomaterials have not yet been established. In this study, apoptotic bodies‐mimetic nanovesicles derived from apoptotic fibroblasts (ApoNVs) conjugated with dextran and ischemic cardiac homing peptide (CHP) (ApoNV‐DCs) for ischemia‐reperfusion (IR)‐injured heart treatment are developed. Intravenously injected ApoNV‐DCs actively targeted the ischemic myocardium via conjugation with CHP, and are selectively phagocytosed by macrophages in an infarcted myocardium via conjugation with dextran. ApoNV‐DCs polarized macrophages from the M1 to M2 phenotype, resulting in the attenuation of inflammation. Four weeks after injection, ApoNV‐DCs attenuated cardiac remodeling, preserved blood vessels, and prevented cardiac function exacerbation in IR‐injured hearts. Taken together, the findings may open a new avenue for immunomodulation using targeted delivery of anti‐inflammatory nanovesicles that can be universally applied for various inflammatory diseases.
- Open Access
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (6) , 367-386
Are There Hopeful Therapeutic Strategies to Regenerate the Infarcted Hearts?
Korean Circulation Journal 대한심장학회지 순환기 Oh GC, et al. Korean Circ J. 2023 May;53:e44. https://doi.org/10.4070/kcj.2023.0098
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (6) , 367-386
Open AccessAre There Hopeful Therapeutic Strategies to Regenerate the Infarcted Hearts?
Korean Circulation Journal 대한심장학회지 순환기 Oh GC, et al. Korean Circ J. 2023 May;53:e44. https://doi.org/10.4070/kcj.2023.0098
- Open Access
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (50) , eabn5768
Three-dimensional heart extracellular matrix enhances chemically induced direct cardiac reprogramming
Direct cardiac reprogramming has emerged as a promising therapeutic approach for cardiac regeneration. Full chemical reprogramming with small molecules to generate cardiomyocytes may be more amenable than genetic reprogramming for clinical applications as it avoids safety concerns associated with genetic manipulations. However, challenges remain regarding low conversion efficiency and incomplete cardiomyocyte maturation. Furthermore, the therapeutic potential of chemically induced cardiomyocytes (CiCMs) has not been investigated. Here, we report that a three-dimensional microenvironment reconstituted with decellularized heart extracellular matrix can enhance chemical reprogramming and cardiac maturation of fibroblasts to cardiomyocytes. The resultant CiCMs exhibit elevated cardiac marker expression, sarcomeric organization, and improved electrophysiological features and drug responses. We investigated the therapeutic potential of CiCMs reprogrammed in three-dimensional heart extracellular matrix in a rat model of myocardial infarction. Our platform can facilitate the use of CiCMs for regenerative medicine, disease modeling, and drug screening.
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (50) , eabn5768
Open AccessThree-dimensional heart extracellular matrix enhances chemically induced direct cardiac reprogramming
Direct cardiac reprogramming has emerged as a promising therapeutic approach for cardiac regeneration. Full chemical reprogramming with small molecules to generate cardiomyocytes may be more amenable than genetic reprogramming for clinical applications as it avoids safety concerns associated with genetic manipulations. However, challenges remain regarding low conversion efficiency and incomplete cardiomyocyte maturation. Furthermore, the therapeutic potential of chemically induced cardiomyocytes (CiCMs) has not been investigated. Here, we report that a three-dimensional microenvironment reconstituted with decellularized heart extracellular matrix can enhance chemical reprogramming and cardiac maturation of fibroblasts to cardiomyocytes. The resultant CiCMs exhibit elevated cardiac marker expression, sarcomeric organization, and improved electrophysiological features and drug responses. We investigated the therapeutic potential of CiCMs reprogrammed in three-dimensional heart extracellular matrix in a rat model of myocardial infarction. Our platform can facilitate the use of CiCMs for regenerative medicine, disease modeling, and drug screening.
- Open Access
- 26 July 2022
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 54 (7) , 1061-1063
Author Correction: Human cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair
- 26 July 2022
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 54 (7) , 1061-1063
Open AccessAuthor Correction: Human cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair
- Open Access
- 15 October 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (10) , 1624
Histochrome Attenuates Myocardial Ischemia-Reperfusion Injury by Inhibiting Ferroptosis-Induced Cardiomyocyte Death
Reactive oxygen species (ROS) and intracellular iron levels are critical modulators of lipid peroxidation that trigger iron-dependent non-apoptotic ferroptosis in myocardial ischemia-reperfusion (I/R) injury. Histochrome (HC), with a potent antioxidant moiety and iron-chelating capacity, is now available in clinical practice. However, limited data are available about the protective effects of HC on ferroptotic cell death in myocardial I/R injury. In this study, we investigated whether the intravenous administration of HC (1 mg/kg) prior to reperfusion could decrease myocardial damage by reducing ferroptosis. Rats undergoing 60 min of ischemia and reperfusion were randomly divided into three groups as follows: (1) Sham, (2) I/R control, and (3) I/R + HC. Serial echocardiography up to four weeks after I/R injury showed that intravenous injection of HC significantly improved cardiac function compared to the I/R controls. In addition, the hearts of rats who received intravenous injection of HC exhibited significantly lower cardiac fibrosis and higher capillary density. HC treatment decreased intracellular and mitochondrial ROS levels by upregulating the expression of nuclear factor erythroid 2-related factor (Nrf2) and its downstream genes. HC also inhibited erastin- and RSL3-induced ferroptosis in rat neonatal cardiomyocytes by maintaining the intracellular glutathione level and through upregulated activity of glutathione peroxidase 4. These findings suggest that early intervention with HC before reperfusion rescued myocardium from I/R injury by preventing ferroptotic cell death. Therefore, HC is a promising therapeutic option to provide secondary cardioprotection in patients who undergo coronary reperfusion therapy.
- 15 October 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (10) , 1624
Open AccessHistochrome Attenuates Myocardial Ischemia-Reperfusion Injury by Inhibiting Ferroptosis-Induced Cardiomyocyte Death
Reactive oxygen species (ROS) and intracellular iron levels are critical modulators of lipid peroxidation that trigger iron-dependent non-apoptotic ferroptosis in myocardial ischemia-reperfusion (I/R) injury. Histochrome (HC), with a potent antioxidant moiety and iron-chelating capacity, is now available in clinical practice. However, limited data are available about the protective effects of HC on ferroptotic cell death in myocardial I/R injury. In this study, we investigated whether the intravenous administration of HC (1 mg/kg) prior to reperfusion could decrease myocardial damage by reducing ferroptosis. Rats undergoing 60 min of ischemia and reperfusion were randomly divided into three groups as follows: (1) Sham, (2) I/R control, and (3) I/R + HC. Serial echocardiography up to four weeks after I/R injury showed that intravenous injection of HC significantly improved cardiac function compared to the I/R controls. In addition, the hearts of rats who received intravenous injection of HC exhibited significantly lower cardiac fibrosis and higher capillary density. HC treatment decreased intracellular and mitochondrial ROS levels by upregulating the expression of nuclear factor erythroid 2-related factor (Nrf2) and its downstream genes. HC also inhibited erastin- and RSL3-induced ferroptosis in rat neonatal cardiomyocytes by maintaining the intracellular glutathione level and through upregulated activity of glutathione peroxidase 4. These findings suggest that early intervention with HC before reperfusion rescued myocardium from I/R injury by preventing ferroptotic cell death. Therefore, HC is a promising therapeutic option to provide secondary cardioprotection in patients who undergo coronary reperfusion therapy.
- Open Access
- 28 September 2021
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 53 (9) , 1423-1436
Human cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair
Stem cell-based therapies with clinical applications require millions of cells. Therefore, repeated subculture is essential for cellular expansion, which is often complicated by replicative senescence. Cellular senescence contributes to reduced stem cell regenerative potential as it inhibits stem cell proliferation and differentiation as well as the activation of the senescence-associated secretory phenotype (SASP). In this study, we employed MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, and examined its long-term priming effect on the activities of senile human cardiac stem cells (hCSCs) and the functional benefits of primed hCSCs after transplantation. In vitro experiments showed that the MHY-1685‒primed hCSCs exhibited higher viability in response to oxidative stress and an enhanced proliferation potential compared to that of the unprimed senile hCSCs. Interestingly, priming MHY-1685 enhanced the expression of stemness-related markers in senile hCSCs and provided the differentiation potential of hCSCs into vascular lineages. In vivo experiment with echocardiography showed that transplantation of MHY-1685‒primed hCSCs improved cardiac function than that of the unprimed senile hCSCs at 4 weeks post-MI. In addition, hearts transplanted with MHY-1685-primed hCSCs exhibited significantly lower cardiac fibrosis and higher capillary density than that of the unprimed senile hCSCs. In confocal fluorescence imaging, MHY-1685‒primed hCSCs survived for longer durations than that of the unprimed senile hCSCs and had a higher potential to differentiate into endothelial cells (ECs) within the infarcted hearts. These findings suggest that MHY-1685 can rejuvenate senile hCSCs by modulating autophagy and that as a senescence inhibitor, MHY-1685 can provide opportunities to improve hCSC-based myocardial regeneration.
- 28 September 2021
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 53 (9) , 1423-1436
Open AccessHuman cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair
Stem cell-based therapies with clinical applications require millions of cells. Therefore, repeated subculture is essential for cellular expansion, which is often complicated by replicative senescence. Cellular senescence contributes to reduced stem cell regenerative potential as it inhibits stem cell proliferation and differentiation as well as the activation of the senescence-associated secretory phenotype (SASP). In this study, we employed MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, and examined its long-term priming effect on the activities of senile human cardiac stem cells (hCSCs) and the functional benefits of primed hCSCs after transplantation. In vitro experiments showed that the MHY-1685‒primed hCSCs exhibited higher viability in response to oxidative stress and an enhanced proliferation potential compared to that of the unprimed senile hCSCs. Interestingly, priming MHY-1685 enhanced the expression of stemness-related markers in senile hCSCs and provided the differentiation potential of hCSCs into vascular lineages. In vivo experiment with echocardiography showed that transplantation of MHY-1685‒primed hCSCs improved cardiac function than that of the unprimed senile hCSCs at 4 weeks post-MI. In addition, hearts transplanted with MHY-1685-primed hCSCs exhibited significantly lower cardiac fibrosis and higher capillary density than that of the unprimed senile hCSCs. In confocal fluorescence imaging, MHY-1685‒primed hCSCs survived for longer durations than that of the unprimed senile hCSCs and had a higher potential to differentiate into endothelial cells (ECs) within the infarcted hearts. These findings suggest that MHY-1685 can rejuvenate senile hCSCs by modulating autophagy and that as a senescence inhibitor, MHY-1685 can provide opportunities to improve hCSC-based myocardial regeneration.
- Open Access
- 1 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1449
In Situ Preconditioning of Human Mesenchymal Stem Cells Elicits Comprehensive Cardiac Repair Following Myocardial Infarction
Human bone marrow-derived mesenchymal stem cells (BM-MSCs), represented as a population of adult stem cells, have long been considered as one of the most promising sources for cell-based cardiac regenerative therapy. However, their clinical use has been significantly hampered by low survival and poor retention following administration into failing hearts. Here, to improve the therapeutic effectiveness of BM-MSCs, we examined a novel therapeutic platform named in situ preconditioning in a rat myocardial infarction (MI) model. In situ preconditioning was induced by a combinatory treatment of BM-MSCs with genetically engineered hepatocyte growth factor-expressing MSCs (HGF-eMSCs) and heart-derived extracellular matrix (hdECM) hydrogel. Subsequently, our results demonstrated that in situ preconditioning with cell mixture substantially improved the survival/retention of BM-MSCs in the MI-induced rat hearts. Enhanced retention of BM-MSCs ultimately led to a significant cardiac function improvement, which was derived from the protection of myocardium and enhancement of vessel formation in the MI hearts. The results provide compelling evidence that in situ preconditioning devised to improve the therapeutic potential of BM-MSCs can be an effective strategy to achieve cardiac repair of MI hearts.
- 1 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1449
Open AccessIn Situ Preconditioning of Human Mesenchymal Stem Cells Elicits Comprehensive Cardiac Repair Following Myocardial Infarction
Human bone marrow-derived mesenchymal stem cells (BM-MSCs), represented as a population of adult stem cells, have long been considered as one of the most promising sources for cell-based cardiac regenerative therapy. However, their clinical use has been significantly hampered by low survival and poor retention following administration into failing hearts. Here, to improve the therapeutic effectiveness of BM-MSCs, we examined a novel therapeutic platform named in situ preconditioning in a rat myocardial infarction (MI) model. In situ preconditioning was induced by a combinatory treatment of BM-MSCs with genetically engineered hepatocyte growth factor-expressing MSCs (HGF-eMSCs) and heart-derived extracellular matrix (hdECM) hydrogel. Subsequently, our results demonstrated that in situ preconditioning with cell mixture substantially improved the survival/retention of BM-MSCs in the MI-induced rat hearts. Enhanced retention of BM-MSCs ultimately led to a significant cardiac function improvement, which was derived from the protection of myocardium and enhancement of vessel formation in the MI hearts. The results provide compelling evidence that in situ preconditioning devised to improve the therapeutic potential of BM-MSCs can be an effective strategy to achieve cardiac repair of MI hearts.